MoonLake Immunotherapeutics (MLTX)
After hours:
| Previous close | 44.52 |
| Open | 43.81 |
| Bid | 43.63 x 100 |
| Ask | 43.88 x 100 |
| Day's range | 41.75 - 44.37 |
| 52-week range | 24.31 - 64.98 |
| Volume | |
| Avg. volume | 470,491 |
| Market cap | 2.745B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings date | 12 May 2024 - 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 71.00 |
- GuruFocus.com
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
Details on Clinical Advances and Financial Health Amidst Ongoing Research and Development Efforts
GlobeNewswireMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA)
Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland, April 10, 2024--MoonLake Immunotherapeutics ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active
